Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2508-2517

  Zuo, Jian Hong ^a,b   Zhu, Wei ^a,b   Li, Mao Yu ^a   Li, Xin Hui ^a   Yi, Hong ^a   Zeng, Gu Qing ^a   Wan, Xun Xun ^a   He, Qiu Yan ^a   Li, Jian Huang ^a   Qu, Jia Quan ^a   Chen, Yu ^a   Xiao, Zhi Qiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

E cadherin; EGFR; HNSCC; Invasion; MMP 9

Indexed keywords

ALPHA TUBULIN; EPIDERMAL GROWTH FACTOR; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL LINE; CELL MIGRATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84860389234     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23175     Document Type: Article

References (49)

1. Ballo H, Koldovsky P, Hoffmann T, Balz V, Hildebrandt B, Gerharz CD, Bier H,. 1999. Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model. Anticancer Res 19: 3827-3836.
2. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D,. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
3. Bernier J, Bentzen SM, Vermorken JB,. 2009. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6: 266-277.
4. Berx G, Becker KF, Hofler H, van Roy F,. 1998. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12: 226-237. (Pubitemid 28418891)
5. Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF, Li C, Li JL, Liu YF, Chen ZC, Xiao ZQ,. 2008. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 7: 5254-5262.
6. Chen LF, Cohen EE, Grandis JR,. 2010. New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 16: 2489-2495.
7. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML,. 2006. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 66: 32-48. (Pubitemid 43005947)
8. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP,. 2009. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 15: 6529-6540.
9. Eriksen JG, Steiniche T, Sogaard H, Overgaard J,. 2004. Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. Apmis 112: 560-568. (Pubitemid 40040183)
10. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W,. 1991. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185. (Pubitemid 21909684)
11. Fung C, Grandis JR,. 2010. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 15: 355-373.
12. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S,. 2004. Head and neck cancer: Meeting summary and research opportunities. Cancer Res 64: 8126-8129. (Pubitemid 39446952)
13. Hoffmann T, Hafner D, Ballo H, Haas I, Bier H,. 1997. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 17: 4419-4425. (Pubitemid 28081723)
14. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB,. 2007. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67: 3106-3116. (Pubitemid 46724847)
15. Jetten AM, Kim JS, Sacks PG, Rearick JI, Lotan D, Hong WK, Lotan R,. 1990. Inhibition of growth and squamous-cell differentiation markers in cultured human head and neck squamous carcinoma cells by beta-all-trans retinoic acid. Int J Cancer 45: 195-202. (Pubitemid 20032121)
16. Kalyankrishna S, Grandis JR,. 2006. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672. (Pubitemid 46622088)
17. Kang Y, Massague J,. 2004. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118: 277-279. (Pubitemid 39061108)
18. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J,. 2009. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9: 188.
19. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN,. 2010. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29: 2047-2059.
20. Le Tourneau C, Faivre S, Siu LL,. 2007. Molecular targeted therapy of head and neck cancer: Review and clinical development challenges. Eur J Cancer 43: 2457-2466. (Pubitemid 350086931)
21. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C,. 2009. Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol 34: 897-903.
22. Lin MT, Chang CC, Lin BR, Yang HY, Chu CY, Wu MH, Kuo ML,. 2007. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. J Biol Chem 282: 34594-34604.
23. Lungu G, Covaleda L, Mendes O, Martini-Stoica H, Stoica G,. 2008. FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-kappaB and activating protein-1. Mol Carcinog 47: 424-435. (Pubitemid 351822301)
24. Malemud CJ,. 2006. Matrix metalloproteinases (MMPs) in health and disease: An overview. Front Biosci 11: 1696-1701. (Pubitemid 43253387)
25. Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J,. 2003. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 129: 631-641. (Pubitemid 37452629)
26. Marsit CJ, Posner MR, McClean MD, Kelsey KT,. 2008. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 113: 1566-1571.
27. Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S,. 1989. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18: 391-395. (Pubitemid 20001923)
28. Natalwala A, Spychal R, Tselepis C,. 2008. Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J Gastroenterol 14: 3792-3797.
29. Nieuwenhuis EJ, Leemans CR, Kummer JA, Denkers F, Snow GB, Brakenhoff RH,. 2003. Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab Invest 83: 1233-1240. (Pubitemid 37013058)
30. Oc P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, Eccles SA,. 2000. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60: 1121-1128. (Pubitemid 30129555)
31. Reuter CW, Morgan MA, Eckardt A,. 2007. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96: 408-416. (Pubitemid 46215210)
32. Rosenthal EL, Matrisian LM,. 2006. Matrix metalloproteases in head and neck cancer. Head Neck 28: 639-648. (Pubitemid 44025114)
33. Ruhul Amin AR, Senga T, Oo ML, Thant AA, Hamaguchi M,. 2003. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: A role for the dual signalling pathways, Akt and Erk. Genes Cells 8: 515-523. (Pubitemid 36748455)
34. Schaaij-Visser TB, Graveland AP, Gauci S, Braakhuis BJ, Buijze M, Heck AJ, Kuik DJ, Bloemena E, Leemans CR, Slijper M, Brakenhoff RH,. 2009. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. Clin Cancer Res 15: 7666-7675.
35. Schmalhofer O, Brabletz S, Brabletz T,. 2009. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
36. Sen T, Dutta A, Maity G, Chatterjee A,. 2010. Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. Biochimie 92: 1422-1434.
37. Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, Beder LB, Demircan K, Fujii M, Yamanaka N, Shimizu K, Grenman R, Nagai N,. 2008. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99: 1589-1594.
38. Stamenkovic I,. 2000. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433. (Pubitemid 32181912)
39. Stamenkovic I,. 2003. Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol 200: 448-464. (Pubitemid 36818245)
40. Swango PA,. 1996. Cancers of the oral cavity and pharynx in the United States: An epidemiologic overview. J Public Health Dent 56: 309-318. (Pubitemid 126701498)
41. Thant AA, Nawa A, Kikkawa F, Ichigotani Y, Zhang Y, Sein TT, Amin AR, Hamaguchi M,. 2000. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 18: 423-428. (Pubitemid 32588623)
42. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR,. 2003. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 63: 5629-5635. (Pubitemid 37139888)
43. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ,. 2007. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67: 9304-9314. (Pubitemid 47535919)
44. Valkova C, Mertens C, Weisheit S, Imhof D, Liebmann C,. 2010. Activation by tyrosine phosphorylation as a prerequisite for protein kinase C{zeta} to mediate epidermal growth factor receptor signaling to ERK. Mol Cancer Res 8: 783-797.
45. van Roy F, Berx G,. 2008. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 65: 3756-3788.
46. Vleminckx K, Vakaet L Jr. , Mareel M, Fiers W, van Roy F,. 1991. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119. (Pubitemid 121001351)
47. Yang LJ, Liu YQ, Gu B, Bian XC, Feng HL, Yang ZL, Liu YY,. 2010. Effect of forced E-cadherin expression on adhesion and proliferation of human breast carcinoma cells. Zhonghua Bing Li Xue Za Zhi 39: 842-847.
48. Zhou H, Kramer RH,. 2005. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. J Biol Chem 280: 10624-10635. (Pubitemid 40395924)
49. Zuo J, Ishikawa T, Boutros S, Xiao Z, Humtsoe JO, Kramer RH,. 2010. Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Mol Cancer Res 8: 170-182.